Overview of Novel Treatments for Retinal Vascular Diseases

Opinion
Video

A panelist discusses novel treatments for retinal vascular diseases, including faricimab, aflibercept, and ranibizumab.

Video content above is prompted by the following:
Could you briefly provide an overview of the new treatments available for retinal vascular diseases?

  1. Faricimab
  2. Aflibercept 8mg
  3. Port delivery device with ranibizumab
Recent Videos
3 experts are featured in this series.
Vikas Chopra at AAO 2024: Advancements in MIGS are transforming patient care
AAO 2024: Bonnie An Henderson, MD, talks about advancing medical education with AI, robotics, and diverse learning methods
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Marjorie Rah, OD, PhD, FAAO
Professor Shahina Pardhan, BSC, PhD, MBCO, H DHealth Brad, Director of the Vision and Eye Research Institute, School of Medicine, at Anglia Ruskin University in Cambridge, United Kingdom.
© 2024 MJH Life Sciences

All rights reserved.